Adjuvant therapy in hepatocellular carcinoma: the IMbrave050 trial

Lancet. 2024 Aug 17;404(10453):654-655. doi: 10.1016/S0140-6736(24)00797-9.

Authors

Hyunjae Shin¹, Jeong-Hoon Lee²

Affiliations

¹ Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul 03080, South Korea; Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, South Korea.
² Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul 03080, South Korea. Electronic address: pindra@empal.com.

PMID: 39153810
DOI: 10.1016/S0140-6736(24)00797-9

No abstract available

Publication types

Letter
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use
Antineoplastic Agents* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bevacizumab / therapeutic use
Carcinoma, Hepatocellular* / drug therapy
Chemotherapy, Adjuvant
Humans
Immune Checkpoint Inhibitors / therapeutic use
Liver Neoplasms* / drug therapy
Liver Neoplasms* / pathology
Randomized Controlled Trials as Topic

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
atezolizumab
Bevacizumab
Immune Checkpoint Inhibitors